【摘要】 应用ＢＣＯＰＰ／ＣＨＯＰ－Ｂ交替联合化疗方案，治疗６０例中度及高度恶性非何杰金淋巴瘤（ＮＨＬ），完全缓解率（ＣＲ）为６０％，３年生存率为５６．８％。中度恶性组、体力状况０及１级、临床分期Ⅰ、Ⅱ、Ⅲ期和Ａ组患者３年生存率分别为８０．６％、８７．１％、６３．１％和７４．８％，高度恶性组、体力分级≥２级、Ⅳ期、Ｂ症状和血清乳酸脱氢酶（ＬＤＨ）≥３．３４μｍｏｌ·Ｓ／Ｌ患者预后不良，３年生存率分别为２７．５％、７．０％、３４．２％、１２．８％和２２．５％。上述结果表明本化疗方案更适用于治疗较早期（Ⅰ、Ⅱ、Ⅲ期）的中度恶性ＮＨＬ患者。更多还原

【Abstract】 patients with intermediate or high grade non-Hodgkin lymphoma (NHL) were treated with BCOPP/CHOP-B regimen, 36 patients(60%)achieved a complete remission(CR)after 6～8cycles of chemotherapy. The overall survival at three years was 56.8%. Three-year survival rates for the patients with intermediate grade subtype,performance status 0 and 1 grade, clinic stage Ⅰ,Ⅱand Ⅲ, and without "B" symptoms,were 80.6%,87.1%,63.1%and 74.8%respectively. The prognosis was poor with high grade subtype, performance status≥2grade,stage Ⅳ"B" symptoms and LDH≥3. 34μmol·S/L, Three-year survival rate was 27.5%in high grade group,7.0%in performance status≥2 group, 34.2% in stage Ⅳ group, 12.8% in"B" symptom group and 22.5%in LDH≥200U/L group, The results illustrated that the regimen was more satisfactory for the patients with intermediate grade NHL at in each stage(Ⅰ、Ⅱ、Ⅲ).更多还原